Novel drug combination showed antitumor activity in patients with incurable BRCA-deficient cancers
Sunday, April 7, 2013 - 22:30
in Health & Medicine
When given sequentially, two orally available experimental drugs -- sapacitabine and seliciclib -- worked together to elicit antitumor effects in patients with incurable BRCA-deficient cancers, according to phase I data.